The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

Overview

Journal Target Oncol

Specialty Oncology

Date 2016 May 18

PMID 27184491

Citations 11

Authors

Marco Puzzoni

Nicola Silvestris

Francesco Leone

Riccardo Giampieri

Luca Faloppi

Laura Demurtas

Emanuela DellAquila

Donatella Marino

Oronzo Brunetti

Silvio Ken Garattini

Elena Ongaro

Giorgio Astara

Laura Orgiano

Giuseppe Aprile

Daniele Santini

Mario Scartozzi

Affiliations

Soon will be listed here.

Abstract

The encouraging results in immunotherapy for melanoma also led the way for translational and clinical research about immune-related mechanisms possibly relevant for gastrointestinal tumours. It is in fact now evident that the immune checkpoint modulation and in particular cell-mediated immune-response through programmed cell death-1 (PD-1) and the cytotoxic T-lymphocyte antigen-4 (CTLA4) receptors along with the regulatory T cells activity all have a relevant role in gastrointestinal cancers as well. This review aims to explore the state of the art of immunotherapy for gastrointestinal tumours, deepening recent scientific evidence regarding anti PD-1/PDL-1 and anti CTLA4 monoclonal antibodies, peptide based vaccine, DNA based vaccine, and pulsed dendritic cells, either alone or in combination with other antineoplastic medical therapy and locoregional treatments. Considering the non-negligible toxicity profile deriving from such a treatment approach, predictive biomarkers of response to immunotherapy in gastrointestinal cancer are also urgently needed in order to better select the patients' group with the highest likelihood of benefit.

Citing Articles

Three-dimensional heterotypic colorectal cancer spheroid models for evaluation of drug response.

Yau J, Adriani G Front Oncol. 2023; 13:1148930.

PMID: 37469395 PMC: 10352797. DOI: 10.3389/fonc.2023.1148930.

The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis.

He Q, Li J, Zhang C, Tang S, Ren Q Transl Cancer Res. 2022; 9(11):6780-6791.

PMID: 35117287 PMC: 8798721. DOI: 10.21037/tcr-20-1975.

Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).

Lampis A, Ratti M, Ghidini M, Mirchev M, Okuducu A, Valeri N Int J Mol Med. 2021; 47(6).

PMID: 33846775 PMC: 8041478. DOI: 10.3892/ijmm.2021.4930.

Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication.

Wang W, Wu M, Liu M, Yan Z, Wang G, Mao D J Immunother Cancer. 2020; 8(1).

PMID: 32581041 PMC: 7312344. DOI: 10.1136/jitc-2020-000793.

Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?.

Musacchio L, Boccia S, Caruso G, Santangelo G, Fischetti M, Tomao F J Clin Med. 2020; 9(6).

PMID: 32503218 PMC: 7356971. DOI: 10.3390/jcm9061721.

References

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25):2654-66. DOI: 10.1056/NEJMoa051424. View

Mundy-Bosse B, Young G, Bauer T, Binkley E, Bloomston M, Bill M . Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011; 60(9):1269-79. PMC: 3521517. DOI: 10.1007/s00262-011-1029-z. View

Lodoen M, Lanier L . Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006; 18(4):391-8. PMC: 7127478. DOI: 10.1016/j.coi.2006.05.002. View

Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. DOI: 10.1038/nrc3973. View

Maeda K, Hazama S, Tokuno K, Kan S, Maeda Y, Watanabe Y . Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. Anticancer Res. 2011; 31(12):4569-74. View

Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T . PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001; 98(24):13866-71. PMC: 61133. DOI: 10.1073/pnas.231486598. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Tsuchiyama T, Nakamoto Y, Sakai Y, Marukawa Y, Kitahara M, Mukaida N . Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J Immunol. 2006; 178(1):574-83. DOI: 10.4049/jimmunol.178.1.574. View

Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K . Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012; 41(4):1297-304. DOI: 10.3892/ijo.2012.1573. View

10.

Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H . Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002; 8(6):1767-71. View

11.

Gabitass R, Annels N, Stocken D, Pandha H, Middleton G . Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60(10):1419-30. PMC: 3176406. DOI: 10.1007/s00262-011-1028-0. View

12.

Sandel M, Speetjens F, Menon A, Albertsson P, Basse P, Hokland M . Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol. 2004; 42(4):541-6. DOI: 10.1016/j.molimm.2004.07.039. View

13.

Correa P . Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995; 19 Suppl 1:S37-43. View

14.

Tiegs G, Lohse A . Immune tolerance: what is unique about the liver. J Autoimmun. 2009; 34(1):1-6. DOI: 10.1016/j.jaut.2009.08.008. View

15.

Lee J, Lee J, Lim Y, Yeon J, Song T, Yu S . Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015; 148(7):1383-91.e6. DOI: 10.1053/j.gastro.2015.02.055. View

16.

Parkhurst M, Yang J, Langan R, Dudley M, Nathan D, Feldman S . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2010; 19(3):620-6. PMC: 3048186. DOI: 10.1038/mt.2010.272. View

17.

Topalian S, Drake C, Pardoll D . Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24(2):207-12. PMC: 3319479. DOI: 10.1016/j.coi.2011.12.009. View

18.

Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A . VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015; 212(2):139-48. PMC: 4322048. DOI: 10.1084/jem.20140559. View

19.

Jiang J, Shen Y, Wu C, Zhu Y, Wei W, Chen L . Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol. 2010; 16(48):6155-62. PMC: 3012571. DOI: 10.3748/wjg.v16.i48.6155. View

20.

Lipson E, Sharfman W, Drake C, Wollner I, Taube J, Anders R . Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2012; 19(2):462-8. PMC: 3548952. DOI: 10.1158/1078-0432.CCR-12-2625. View